Recro Pharma Reports Third Quarter 2019 Financial Results
November 08, 2019 07:00 ET
|
Recro Pharma, Inc.
CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100...
Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019
November 05, 2019 16:05 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report third quarter financial results on Friday, November 8, 2019. Recro's management...
Recro Pharma’s Board of Directors Approves Separation of Acute Care Business Segment and Declares Special Dividend Distribution of Baudax Bio Common Stock
November 05, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing...
FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application
October 31, 2019 07:00 ET
|
Recro Pharma, Inc.
Received Positive Response from FDA Regarding IV Meloxicam Formal Dispute Resolution Request Company Remains on Track to Execute Spin Out of Acute Care Business Segment During the Fourth Quarter of...
Recro Pharma Reports Second Quarter 2019 Financial Results
August 08, 2019 07:14 ET
|
Recro Pharma, Inc.
Record Results and Raising Guidance Announces Plan to Spin Acute Care Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc....
Recro Pharma to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
August 01, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a pharmaceutical company with a high-performing, revenue generating contract development and manufacturing (CDMO)...
Recro Pharma to Present at Upcoming Investor Conferences
May 30, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and...
Recro Pharma Reports First Quarter 2019 Financial Results
May 10, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Philadelphia, May 10, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO)...
Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019
May 06, 2019 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report first quarter financial results on Friday, May 10, 2019. Recro's management team...
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville
April 16, 2019 07:00 ET
|
Recro Pharma, Inc.
Company Continues Important, Strategic Relationship with Key Global Customer; Long-Term Contract Executed Teva to Continue to be Exclusive Marketing Partner of Verapamil SR® Capsules with Same...